Physician profile
Michael Dolen
NPI 1588960165
$2,647.54
in general payments reported to CMS, 2019-2025
31 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $244 · 2021: $329 · 2022: $199 · 2023: $497 · 2024: $495 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $633.30 | 2019-2024 | Wegovy, Sogroya |
| Organogenesis INC. | $322.05 | 2019-2024 | Puraply, Affinity |
| Dexcom, INC. | $243.43 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $213.98 | 2019-2025 | Jardiance, Mounjaro, Lyumjev |
| Smith+Nephew, INC. | $199.63 | 2019-2024 | Collagenase Santyl, Regranex, Grafix Pl |
| Amgen INC. | $115.23 | 2021-2024 | Prolia, Evenity |
| Nevro Corp. | $112.44 | 2024 | Senza |
| Insulet Corporation | $77.66 | 2023-2024 | Omnipod |
| Averitas Pharma INC. | $66.09 | 2023 | Qutenza |
| Melinta Therapeutics, LLC | $58.80 | 2019 | |
| Corcept Therapeutics | $58.04 | 2019-2025 | Korlym |
| Tolmar, INC. | $53.09 | 2024-2025 | Jatenzo |
| Advanced Oxygen Therapy INC. | $47.82 | 2021-2023 | Topical Oxygen Chamber For Extremities |
| Janssen Pharmaceuticals, INC | $42.60 | 2019 | |
| Ibsa Pharma INC. | $42.21 | 2023-2024 | Tirosint, Licart, Tirosint |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $37.50 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $34.39 | 2025 | Nuzyra |
| Abbvie INC. | $33.22 | 2023 | Dalvance |
| Grt US Holding, INC. | $32.74 | 2022 | |
| Becton, Dickinson and Company | $27.11 | 2021-2022 | |
| Hydrofera LLC | $25.92 | 2024 | Hydrofera Blue |
| Musculoskeletal Transplant Foundation INC. | $23.87 | 2023 | |
| Misonix INC | $22.55 | 2020 | |
| Globus Medical, INC. | $21.49 | 2025 | Senza |
| Kerecis Limited | $19.67 | 2022 | |
| Amarin Pharma, INC. | $17.35 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.82 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.54 | 2022 | |
| Recordati_rare_diseases_inc. | $13.31 | 2023 | Signifor Lar, Isturisa |
| Sanofi-Aventis U.S. LLC | $12.96 | 2019 | |
| Amryt Pharma Holdings LTD | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dolen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.